Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation

Kaloyannidis, Panayotis; Hertzberg, Mark; Webb, Kate; Zomas, Athanasios; Schrover, Rudolf; Hurst, Michael; Jacob, I.; Nikoglou, E; M. Connors, Joseph

doi:10.1111/bjh.16201

Public

Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation

Published in British Journal of Haematology • Oct 6, 2019

Authors:

Panayotis Kaloyannidis

Mark Hertzberg

Kate Webb

Abstract

Brentuximab vedotin (BV) is the first approved novel agent for salvage treatment of relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after autologous stem cell transplantation (ASCT). In this study, a literature-based analysis was undertaken to assess, via an indirect treatment comparis...

Subject

Brentuximab vedotin

Medicine

Autologous stem-cell transplantation

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!